Maze Therapeutics, Inc. (MAZE)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
Key ratios (FY2025)
-36.9%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | — | $167.50M | — |
| Operating Income | -$142.90M | $57.59M | — |
| Net Income | -$131.12M | $52.23M | — |
| EPS (Diluted) | $-3.05 | $1.25 | — |
| Total Assets | $397.13M | $240.54M | — |
| Total Liabilities | $42.16M | $43.64M | — |
| Shareholders' Equity | $354.97M | -$311.18M | -$373.85M |
| Cash & Equivalents | $189.25M | $196.81M | — |
| Operating Cash Flow | -$111.94M | $75.95M | — |
| Capital Expenditures | $794.0K | $1.15M | — |
| Shares Outstanding | 49.34M | 2.45M | — |